Clinical efficacy and safety of docetaxel, oxaliplatin and S -1 neoadjuvant chemotherapy in the treatment of upper gastric cancer
10.13699/j.cnki.1001-6821.2015.09.013
- VernacularTitle:多西他赛联合奥沙利铂及替吉奥新辅助化疗对局部晚期胃上部癌的疗效及安全性评价
- Author:
Jin-Xi HUANG
1
;
Tie-Jun YANG
;
Cheng-Hu WANG
;
Yi HOU
;
Xiao-Bing CHEN
Author Information
1. 郑州大学 附属肿瘤医院普外科
- Keywords:
upper gastric cancer;
docetaxel;
oxaliplatin;
S-1;
neoadjuvant chemotherapy
- From:
The Chinese Journal of Clinical Pharmacology
2015;(9):722-724
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of docetaxel, oxaliplatin and S -1 neoadjuvant chemotherapy in the treat-ment of upper gastric cancer.Methods Nine cases with locally advanced upper gastric cancer recruited in this study.After recruited, the patients were given docetaxel 40 mg · m-2 through intravenous drip infusion in one hour on day 1 and 8, with anti-anaphylactic treatment, oxaliplatin 75 mg· m-2 through intravenous drip infusion in two hours on day 1, and S-1 40 to 60 mg po, twice a day on day 1 to day 14.All of the included patients received 2 cycles with 21 days percycle.After 2 cycles of neoadjuvant chemotherapy, the data of clinical efficacy and toxicity were evaluated.Results All of subjects finished the scheduled chemotherapy regiment.One case reached complete response ( CR, 11.1%) , 6 cases reached partial response ( PR, 66.7%) , and 1 patients had progress disease ( PD, 11.1%).The total response rate was 88.9%.Only 1 case of progress disease didn′t receive the surgery.And the 8 patients received surgery also received 4 cycles of post -surgery chemotherapy with the same regiment.Until October, all the 8 patients were alive without relapse or metastases.The general adverse reactions for neoadjuvant chemotherapy were myelosuppression, gastrointestinal toxicity and peripheral neuritis. No chemotherapy-related death was found in this study.Conclusion Docetaxel, oxaliplatin and S -1 neoadjuvant chemotherapy in the treatment of upper gastric cancer can improve the surgery rate and prognosis.
